

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Ataxia	Nemo-like kinase (NLK)	<p>Fly and mouse studies suggest inhibiting NLK could help treat spinocerebellar ataxia type 1 (SCA1). In a fly model for SCA1, an <i>nlk</i> deficiency decreased markers of disease compared with no deficiency. In the fly model, expression of human <i>NLK</i> increased markers of disease compared with expression of a kinase-dead mutant. In a mouse model for SCA1, lower <i>Nlk</i> expression decreased disease-associated behaviors compared with wild-type <i>Nlk</i> expression. Next steps include understanding additional mechanisms downstream of NLK in diseased and normal brain function.</p> <p><b>SciBX 6(25); doi:10.1038/scibx.2013.631</b>  <b>Published online June 27, 2013</b></p>	Patent and licensing status undisclosed	<p>Ju, H. <i>et al. J. Neurosci.</i>; published online May 29, 2013; doi:10.1523/JNEUROSCI.3465-12.2013  <b>Contact:</b> Janghoo Lim, Yale School of Medicine, New Haven, Conn.                      e-mail:  <a href="mailto:janghoo.lim@yale.edu">janghoo.lim@yale.edu</a></p>